Lim E - Search Results

1

Window of opportunity treatment in breast cancer.

Chen J, Easwaralingam N, Warrier S, Ong A, Carson EK, Mak C, Snook K, Middleton K, Parker A, Palmieri C, Spillane A, Mann GB, Lim E, Segara D. Chen J, et al. Among authors: lim e. ANZ J Surg. 2020 Jan;90(1-2):34-40. doi: 10.1111/ans.15487. Epub 2019 Nov 26. ANZ J Surg. 2020. PMID: 31770829 Review.

2

Optimizing the approach to patients with potentially resectable liver metastases from colorectal cancer.

Lim E, Thomson BN, Heinze S, Chao M, Gunawardana D, Gibbs P. Lim E, et al. ANZ J Surg. 2007 Nov;77(11):941-7. doi: 10.1111/j.1445-2197.2007.04287.x. ANZ J Surg. 2007. PMID: 17931254 Review.

3

Adjuvant endocrine therapy in women with oestrogen-receptor-positive breast cancer: how should the skeletal and vascular side effects be assessed and managed?

Ramchand SK, Lim E, Grossmann M. Ramchand SK, et al. Among authors: lim e. Clin Endocrinol (Oxf). 2016 Nov;85(5):689-693. doi: 10.1111/cen.13172. Epub 2016 Sep 1. Clin Endocrinol (Oxf). 2016. PMID: 27497423 Review.

4

Renewed interest in the progesterone receptor in breast cancer.

Lim E, Palmieri C, Tilley WD. Lim E, et al. Br J Cancer. 2016 Oct 11;115(8):909-911. doi: 10.1038/bjc.2016.303. Epub 2016 Sep 22. Br J Cancer. 2016. PMID: 27657336 Free PMC article. No abstract available.

5

Pushing estrogen receptor around in breast cancer.

Lim E, Tarulli G, Portman N, Hickey TE, Tilley WD, Palmieri C. Lim E, et al. Endocr Relat Cancer. 2016 Dec;23(12):T227-T241. doi: 10.1530/ERC-16-0427. Epub 2016 Oct 11. Endocr Relat Cancer. 2016. PMID: 27729416 Review.

6

Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer.

Lim E, Beith J, Boyle F, de Boer R, Hui R, McCarthy N, Redfern A, Wade T, Woodward N. Lim E, et al. Asia Pac J Clin Oncol. 2018 Oct;14 Suppl 4:12-21. doi: 10.1111/ajco.13065. Asia Pac J Clin Oncol. 2018. PMID: 30288929

7

Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm.

Boyle F, Beith J, Burslem K, de Boer R, Hui R, Lim E, McCarthy N, Redfern A, Woodward N. Boyle F, et al. Among authors: lim e. Asia Pac J Clin Oncol. 2018 Oct;14 Suppl 4:3-11. doi: 10.1111/ajco.13064. Asia Pac J Clin Oncol. 2018. PMID: 30288930

8

Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer.

Portman N, Alexandrou S, Carson E, Wang S, Lim E, Caldon CE. Portman N, et al. Among authors: lim e. Endocr Relat Cancer. 2019 Jan;26(1):R15-R30. doi: 10.1530/ERC-18-0317. Endocr Relat Cancer. 2019. PMID: 30389903 Review.

9

Non-canonical AR activity facilitates endocrine resistance in breast cancer.

Chia K, Milioli H, Portman N, Laven-Law G, Coulson R, Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley WD, Hickey TE, Lim E. Chia K, et al. Among authors: lim e. Endocr Relat Cancer. 2019 Feb 1;26(2):251-264. doi: 10.1530/ERC-18-0333. Endocr Relat Cancer. 2019. PMID: 30557851

10

The International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy Cytopathology.

Field AS, Raymond WA, Rickard M, Arnold L, Brachtel EF, Chaiwun B, Chen L, Di Bonito L, Kurtycz DFI, Lee AHS, Lim E, Ljung BM, Michelow P, Osamura RY, Pinamonti M, Sauer T, Segara D, Tse G, Vielh P, Chong PY, Schmitt F. Field AS, et al. Among authors: lim e. Acta Cytol. 2019;63(4):257-273. doi: 10.1159/000499509. Epub 2019 May 21. Acta Cytol. 2019. PMID: 31112942 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,899 results

Search Page

Filters